Axolotl Biologix Acquired by Private Equity Firm

Axolotl Biologix, a developer of regenerative medicine products, was acquired by a private equity firm. Terms were not disclosed.

The move comes as Axolotl prepares to initiate FDA clinical trials of current and developing biologic products with a range of applications in numerous segments, including orthopedics. Axolotl Biologix...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us